Inflammatory bowel disease (IBD) treatment has progressed significantly over the past decade with the advent of biologics. Anti-tumor necrosis factor (anti-TNF) agents are the most widely available biologics, but the…
The therapeutic approach in inflammatory bowel disease has evolved to target end-organ inflammation to heal intestinal mucosa and avoid structural damage. Objective therapeutic monitoring is required to achieve this goal….
Inflammatory bowel disease (IBD) is an immune-mediated disease and involves a complex interplay of host genetics and environmental influences. Recent advances in the field, including data from genome-wide association studies…
Edward V. Loftus Jr, MD, Editor By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by…
Gary W. Falk, MD, MS, Consulting Editor The therapy of inflammatory bowel disease has changed dramatically in recent years with the advent of biologic therapy. Whereas therapy of inflammatory bowel…
Despite the success of antitumor necrosis factor (TNF) therapy in Crohn’s disease, there remains a need for biologic therapy that targets other immune pathways of disease. Ustekinumab is a fully…
Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target…
Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including…
Biologic therapies, including the anti–tumor necrosis factor-α and cell adhesion molecule inhibitor drugs, have revolutionized the treatment of moderate-to-severe inflammatory bowel disease. Since the introduction of anti–tumor necrosis factor therapies,…
Anti-tumor necrosis factor-α (anti-TNF) agents are frequently used in the treatment of inflammatory bowel disease (IBD). Currently, there are 4 anti-TNF therapies that are Food and Drug Administration–approved for moderate…
